Ichor is dedicated to the clinical application and commercialization
of electroporation-mediated DNA drug
. Ichorís proprietary TriGridô Delivery System uses
electrical fields to increase DNA drug delivery efficiency by up to
1,000 fold as compared to conventional injection. While a number of
approaches have been used for electroporation-mediated DNA drug
delivery in pre-clinical models, clinical implementation has been
hindered by the lack of a reliable and effective means for procedure
administration. Ichorís TriGridô Delivery System platform integrates
key patented design features into simple handheld clinical
electroporation devices that enable safe, efficient, and reproducible
DNA administration and delivery with minimal operator training.
Extensive preclinical studies of in vivo electroporation-mediated DNA
drug delivery performed by Ichor and our partners have demonstrated
that the technique can enable targeted uptake and expression of
DNA plasmids encoding DNA vaccines as well as therapeutic genes.
Clinical results generated using Ichorís electroporation technology
have demonstrated that the procedure is safe and well-tolerated in
humans. Importantly, the dramatic enhancement of immune responses
compared to conventional injection, which has been extensively
documented in animal models, was recently confirmed in a randomized,
placebo controlled human clinical trial of an HIV DNA vaccine.